Navigation Links
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Date:11/11/2008

New Data Presented at the Meeting Demonstrate Vitamin E May Help Prevent

Cardiovascular Events in Hp2-2 Diabetes

MONTVALE, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced new data demonstrating that discontinuation of Vitamin E in patients with the Hp2-2 Diabetes may result in an increased risk of heart attack and rapid deterioration of HDL function. These results were presented today at the Annual Scientific Sessions of the American Heart Association, underway in New Orleans.

"These data demonstrate that after detecting Hp2-2 Diabetes, physicians modified treatment and achieved improved outcomes for specific patients by prescribing vitamin E. These benefits were lost when treatment with vitamin E was abandoned," said Noah Berkowitz, M.D., President and CEO of Synvista Therapeutics. "These types of studies provide confirmation that our clinical laboratory test which determines haptoglobin genotype may be useful in selecting and guiding patient therapy. We believe that the use of our test will be an important facilitator of personalized medicine and will provide a standard by which physicians can influence clinical outcome."

About the Study

In a prospective study called ICARE, 2,241 individuals with diabetes mellitus age 55 or over from 47 primary-care clinics in Israel underwent haptoglobin genotype testing and were randomized to receive either Vitamin E or placebo. The subjects were then followed for three years to track heart attack (myocardial infarction or MI), stroke and death (cardiovascular and all cause). During the study, it was determined that those who had the Hp2-2 genotype and who also received vitamin E had a significantly lower incidence of MI compared to placebo. Also, HDL function was significantly improved in Hp2-2 individuals who took vitamin E, compared to placebo. Following the study, it was discovered that in those Hp2-2 individuals who had received vitamin E, the incidence of MI after stopping vitamin E treatment significantly increased (0.4 percent on vitamin E vs. 1.8 percent off vitamin E, p=0.03). However, only two months after vitamin E withdrawal, HDL function had deteriorated to its level of dysfunction prior to the initiation of the study. Furthermore, in the 15-month period following the termination of the study, there was little demonstrable difference in the incidence of MI in those Hp2-2 individuals who had received vitamin E and stopped taking it after the end of the study compared to those who received placebo (1.8 percent vitamin E vs. 1.7 percent placebo, p=0.9).

About Hp2-2 Diabetes

The best understood function of haptoglobin, a common serum protein, is to bind free hemoglobin released from red blood cells. Extracellular hemoglobin (hemoglobin not found in red blood cells) is a potent oxidizing agent capable of inflicting oxidative tissue damage. Haptoglobin binds to this extracellular hemoglobin and inhibits hemoglobin induced oxidation. Once hemoglobin is bound to haptoglobin, it is rapidly cleared from the bloodstream by the liver or specialized white blood cells.

Haptoglobin in humans exists as three different proteins that arise from one of three haptoglobin gene combinations in the population, Hp 1-1 (16%), Hp2-2 (36%) and Hp1-2 (48%) For a variety of reasons that are well described in medical literature, Hp2-2 is more effective than Hp1-1 at preventing hemoglobin-induced oxidation in the bloodstream and blood vessel wall.

As a result, scientists have determined that the rate of heart disease is five times higher in Hp2-2 diabetes than in Hp1-1 diabetes. Hp2-2 diabetes also has higher rates of myocardial infarction and re-vascularization within one year of angioplasty, and of heart failure and death following a heart attack. Prospective, randomized, clinical trials have demonstrated that the rate of heart attack in Hp2-2 diabetes can be decreased by the administration of natural vitamin E (400IU).

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing clinical laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical test to identify patients with Hp2-2 diabetes. This test, or a similar genetic form of the test, may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure.

For more information, please visit the Company's Web site at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
5. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
6. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
10. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
11. Synvista Therapeutics to be Featured on Wallst.net
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
Breaking Biology Technology:
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):